SV2017005530A - Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituida - Google Patents
Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituidaInfo
- Publication number
- SV2017005530A SV2017005530A SV2017005530A SV2017005530A SV2017005530A SV 2017005530 A SV2017005530 A SV 2017005530A SV 2017005530 A SV2017005530 A SV 2017005530A SV 2017005530 A SV2017005530 A SV 2017005530A SV 2017005530 A SV2017005530 A SV 2017005530A
- Authority
- SV
- El Salvador
- Prior art keywords
- pten
- loss
- combinations
- dihydroimidazo
- pik3r5
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 abstract 3
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 abstract 3
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 abstract 2
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 abstract 2
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 abstract 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 2
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 abstract 2
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 abstract 2
- 101001098116 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit gamma Proteins 0.000 abstract 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 abstract 2
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 abstract 2
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 abstract 2
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 abstract 2
- 101000692672 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 4 Proteins 0.000 abstract 2
- 101000692678 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 5 Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 abstract 2
- 102100026177 Phosphatidylinositol 3-kinase regulatory subunit beta Human genes 0.000 abstract 2
- 102100037553 Phosphatidylinositol 3-kinase regulatory subunit gamma Human genes 0.000 abstract 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 abstract 2
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 abstract 2
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 abstract 2
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 abstract 2
- 102100026481 Phosphoinositide 3-kinase regulatory subunit 4 Human genes 0.000 abstract 2
- 102100026478 Phosphoinositide 3-kinase regulatory subunit 5 Human genes 0.000 abstract 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical compound C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
COMBINACIONES DE: COMPONENTE A : UNO O MÁS COMPUESTOS DE 2,3-DIHIDROIMIDAZO[1,2-C]QUINAZOLINA DE FÓRMULA GENERAL (A1) O (A2), O UNA SAL, SOLVATO, HIDRATO O ESTEREOISÓMERO FISIOLÓGICAMENTE ACEPTABLE DE LOS MISMOS; COMPONENTE B : UNO O MÁS COMPUESTOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-F][1,2,4]-TRIAZIN-4- AMINA SUSTITUIDA DE FÓRMULA GENERAL (B), O UNA SAL, SOLVATO, HIDRATO O ESTEREOISÓMERO FISIOLÓGICAMENTE ACEPTABLE DE LOS MISMOS; EN LAS CUALES OPCIONALMENTE ALGUNOS O TODOS LOS COMPONENTES ESTÁN EN FORMA DE UNA FORMULACIÓN FARMACÉUTICA LA CUAL ESTÁ LISTA PARA SU UTILIZACIÓN Y SE ADMINISTRA SIMULTÁNEA, CONCURRENTE, SEPARADA O CONSECUTIVAMENTE. DEPENDIENTEMENTE UNO DEL OTRO POR LA VÍA ORAL, INTRAVENOSA, TÓPICA, INSTILACIONES LOCALES, INTRAPERITONEAL O NASAL; USO DE DICHAS COMBINACIONES PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE UN CÁNCER; UN KIT QUE COMPRENDE ESE TIPO DE COMBINACIÓN; USO DE BIOMARCADORES QUE ES LA PÉRDIDA DEL SUPRESOR TUMORAL PTEN O FBXW7, PARA PREDECIR LA SENSIBILIDAD Y/O LA RESISTENCIA DE UN PACIENTE CON CÁNCER A DICHO COMPUESTO Y PROPORCIONAR UNA DOSIS FUNDAMENTADA PARA AUMENTAR LA SENSIBILIDAD Y/O PARA SOLUCIONAR LA RESISTENCIA; UN MÉTODO PARA DETERMINAR LA PÉRDIDA DEL SUPRESOR TUMORAL PTEN O FBXW7 ; Y UN MÉTODO PARA DETERMINAR PERTURBACIONES EN PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 Y/O FGFR4. PÉRDIDA DE PTEN Y ALTERACIÓN DE PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 Y/O FGFR4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130418P | 2015-03-09 | 2015-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2017005530A true SV2017005530A (es) | 2018-10-02 |
Family
ID=55538186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2017005530A SV2017005530A (es) | 2015-03-09 | 2017-09-08 | Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituida |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10406162B2 (es) |
| EP (1) | EP3268490B1 (es) |
| JP (1) | JP6867295B2 (es) |
| KR (1) | KR20180013851A (es) |
| CN (1) | CN107864625B (es) |
| AU (1) | AU2016231259A1 (es) |
| BR (1) | BR112017019188A2 (es) |
| CA (1) | CA2978830A1 (es) |
| EA (1) | EA201791974A1 (es) |
| IL (1) | IL254167A0 (es) |
| MX (1) | MX2017011635A (es) |
| PH (1) | PH12017501643A1 (es) |
| SG (1) | SG11201707240SA (es) |
| SV (1) | SV2017005530A (es) |
| WO (1) | WO2016142312A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| KR102736865B1 (ko) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| EP3645005A1 (en) | 2017-06-28 | 2020-05-06 | Bayer Consumer Care AG | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| US11236094B2 (en) * | 2017-08-15 | 2022-02-01 | Cspc Zhongqi Pharmaceuticall Technology (Shijiazhuang) Co., Ltd. | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors |
| WO2019105734A1 (en) * | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN111500587A (zh) * | 2020-04-15 | 2020-08-07 | 湖南省科域生物医药科技有限公司 | Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131159B1 (hr) | 2002-09-30 | 2019-11-01 | Bayer Ip Gmbh | Taljeni azol-pirimidin derivati |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| WO2009091550A2 (en) | 2008-01-14 | 2009-07-23 | Bayer Healthcare Llc | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| CA2796253A1 (en) * | 2010-04-16 | 2011-10-20 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| JP6254087B2 (ja) * | 2011-10-15 | 2017-12-27 | ジェネンテック， インコーポレイテッド | 癌を治療するためのｓｃｄ１アンタゴニスト |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| WO2014191938A1 (en) | 2013-05-31 | 2014-12-04 | Novartis Ag | Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer |
| EP3077002B1 (en) | 2013-12-03 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| KR20180013850A (ko) | 2015-03-09 | 2018-02-07 | 바이엘 파마 악티엔게젤샤프트 | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 |
| JP2019512003A (ja) | 2016-02-01 | 2019-05-09 | バイエル ファーマ アクチエンゲゼルシャフト | コパンリシブバイオマーカー |
| BR112018015782A2 (pt) | 2016-02-01 | 2019-01-02 | Bayer Pharma AG | biomarcadores de copanlisibe |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| AU2020214188A1 (en) * | 2019-01-31 | 2021-07-15 | Bayer Aktiengesellschaft | The monohydrate of rogaratinib hydrochloride and solid states thereof |
-
2016
- 2016-03-07 CN CN201680026204.XA patent/CN107864625B/zh not_active Expired - Fee Related
- 2016-03-07 EA EA201791974A patent/EA201791974A1/ru unknown
- 2016-03-07 WO PCT/EP2016/054727 patent/WO2016142312A1/en not_active Ceased
- 2016-03-07 MX MX2017011635A patent/MX2017011635A/es unknown
- 2016-03-07 KR KR1020177027608A patent/KR20180013851A/ko not_active Withdrawn
- 2016-03-07 BR BR112017019188-1A patent/BR112017019188A2/pt not_active Application Discontinuation
- 2016-03-07 SG SG11201707240SA patent/SG11201707240SA/en unknown
- 2016-03-07 CA CA2978830A patent/CA2978830A1/en not_active Abandoned
- 2016-03-07 EP EP16710115.3A patent/EP3268490B1/en active Active
- 2016-03-07 US US15/556,908 patent/US10406162B2/en not_active Expired - Fee Related
- 2016-03-07 AU AU2016231259A patent/AU2016231259A1/en not_active Abandoned
- 2016-03-07 JP JP2017548224A patent/JP6867295B2/ja not_active Expired - Fee Related
-
2017
- 2017-08-27 IL IL254167A patent/IL254167A0/en unknown
- 2017-09-08 PH PH12017501643A patent/PH12017501643A1/en unknown
- 2017-09-08 SV SV2017005530A patent/SV2017005530A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2978830A1 (en) | 2016-09-15 |
| EA201791974A1 (ru) | 2018-05-31 |
| WO2016142312A1 (en) | 2016-09-15 |
| SG11201707240SA (en) | 2017-10-30 |
| JP2018510869A (ja) | 2018-04-19 |
| JP6867295B2 (ja) | 2021-04-28 |
| MX2017011635A (es) | 2018-02-09 |
| EP3268490A1 (en) | 2018-01-17 |
| PH12017501643A1 (en) | 2018-03-12 |
| CN107864625B (zh) | 2021-05-28 |
| US10406162B2 (en) | 2019-09-10 |
| IL254167A0 (en) | 2017-10-31 |
| CN107864625A (zh) | 2018-03-30 |
| KR20180013851A (ko) | 2018-02-07 |
| US20180055851A1 (en) | 2018-03-01 |
| AU2016231259A1 (en) | 2017-09-21 |
| EP3268490B1 (en) | 2020-07-08 |
| BR112017019188A2 (pt) | 2018-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2017005530A (es) | Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituida | |
| CY1125292T1 (el) | Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
| MX2015002378A (es) | Composicion ansiolitica, formulacion y metodo de uso. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
| ECSP12012261A (es) | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida | |
| BR112016003229A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
| BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
| CL2017002284A1 (es) | Uso de 2,3–dihidroimidazo[1,2–c]quinazolinas sustituidas. | |
| MX2013003695A (es) | Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida. | |
| CY1124893T1 (el) | Φαρμακευτικο μeιγμα μαροπιταντης | |
| CR20160042A (es) | ANTAGONISTAS DE V1a PARA TRATAR TRASTORNOS DEL SUEÑO POR CAMBIO DE FASE | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
| ECSP19027578A (es) | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso | |
| BR112017001375A2 (pt) | agente farmacêutico | |
| BR112016009214A8 (pt) | uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica | |
| BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona | |
| CO2018013792A2 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo | |
| CL2017001941A1 (es) | Uso de una mezcla de polímeros de glucosa modificadas para reducir metastasis de tumor | |
| AR122456A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos |